drugset / Trial / NCT02988960
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Timeline
- Start
- 2017-02-22
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budigalimab | Monoclonal antibody | — | Intravenous |
| Subject | GILORALIMAB | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.